The U.S. agencies announced the conclusion of six significant merger investigations in Q1 2024, double the number seen last quarter. This marks the end of six quarters of three or fewer significant investigations. In line...more
Only 12 significant merger investigations concluded in 2023—a drop of 40 percent from just last year and by far the lowest in DAMITT history. This observed and verifiable drop sharply contrasts with recent reports that...more
The Merger Guidelines lower the market concentration threshold for the presumption that a merger is illegal.
Deals that place combined market shares above 30 percent with a significant increase in concentration are...more
All significant U.S. merger investigations concluded in either a complaint or an abandoned transaction. Three of four quarters over the last year have now concluded without any consent agreements, demonstrating the agencies’...more
On July 19, 2023, the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC) (collectively, the agencies) issued their long-awaited draft Merger Guidelines. The draft Merger Guidelines, once finalized, will...more
Key takeaways - The Federal Trade Commission (FTC) and antitrust agencies in North America and Europe have launched a Task Force to evaluate their current approach to pharmaceutical mergers reviews. The Task Force has sought...more
Key Points:
- This month several U.S. Senators introduced the Preserve Access to Affordable Generics Act. There is no similar bill pending in the U.S. House.
- The Act revives legislative efforts to wipe out the...more